Tenax Therapeutics (TENX) Institutional Ownership $5.92 +0.02 (+0.34%) Closing price 04:00 PM EasternExtended Trading$5.99 +0.07 (+1.18%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Tenax Therapeutics (NASDAQ:TENX)CurrentInstitutional OwnershipPercentage1.67%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$2.10MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$345.86K Get TENX Insider Trade Alerts Want to know when executives and insiders are buying or selling Tenax Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data TENX Institutional Buying and Selling by Quarter Tenax Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 ADAR1 Capital Management LLC68,741$450K0.1%+98.1%1.657% 2/17/2025 Vestal Point Capital LP55,189$342K0.0%-33.8%1.618% 2/17/2025 Two Sigma Investments LP13,521$84K0.0%N/A0.397% 2/17/2025 Millennium Management LLC26,809$166K0.0%N/A0.786% 2/17/2025 Janus Henderson Group PLC166,666$1.03M0.0%N/A4.888% 2/13/2025 ADAR1 Capital Management LLC34,693$215K0.0%-44.4%1.017% 2/12/2025 Geode Capital Management LLC24,354$151K0.0%+32.4%0.714% 11/15/2024 Sphera Funds Management LTD.29,166$101K0.0%N/A0.855% 11/14/2024 Vestal Point Capital LP83,333$288K0.0%N/A2.444% 11/14/2024 Stonepine Capital Management LLC50,000$173K0.1%N/A1.466% 5/1/2023 Virtu Financial LLC84,361$39K0.0%N/A0.377% 11/14/2022 Armistice Capital LLC1,965,885$334K0.0%+23.1%7.799% 11/5/2021 PNC Financial Services Group Inc.70,000$124K0.0%N/A0.278% 10/13/2021Gofen & Glossberg LLC IL3,819,170$6.76M0.2%N/A15.155% 8/16/2021 State Street Corp136,404$296K0.0%N/A0.911% 8/13/2021 Renaissance Technologies LLC192,232$400K0.0%-74.3%1.284% 8/13/2021 Northern Trust Corp34,671$72K0.0%+103.7%0.232% 8/13/2021 Vanguard Group Inc.356,347$742K0.0%+100.3%2.381% 8/12/2021 Dimensional Fund Advisors LP51,895$113K0.0%-14.1%0.347% (Data available from 1/1/2016 forward) TENX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TENX shares? During the previous two years, the following institutional investors and hedge funds held shares of Tenax Therapeutics shares: Janus Henderson Group PLC ($1.03M), ADAR1 Capital Management LLC ($450K), Vestal Point Capital LP ($342K), Stonepine Capital Management LLC ($173K), Millennium Management LLC ($166K), Geode Capital Management LLC ($151K), and Sphera Funds Management LTD. ($101K).Learn more on Tenax Therapeutics' institutional investors. What percentage of Tenax Therapeutics' stock is owned by institutional investors? 1.67% of Tenax Therapeutics' stock is owned by institutional investors. Learn more on TENX's institutional investor holdings. Which institutional investors have been buying Tenax Therapeutics' stock? The following institutional investors have purchased Tenax Therapeutics' stock in the last 24 months: Janus Henderson Group PLC ($166.67K), Vestal Point Capital LP ($83.33K), Stonepine Capital Management LLC ($50K), ADAR1 Capital Management LLC ($34.05K), Sphera Funds Management LTD. ($29.17K), Millennium Management LLC ($26.81K), and Two Sigma Investments LP ($13.52K). How much institutional buying is happening at Tenax Therapeutics? Institutional investors have bought a total of 409,507 shares in the last 24 months. This purchase volume represents approximately $2.10M in transactions. Which of Tenax Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Tenax Therapeutics stock in the last 24 months: Vestal Point Capital LP ($28.14K), and ADAR1 Capital Management LLC ($27.73K). How much institutional selling is happening at Tenax Therapeutics? Institutional investors have sold a total of 55,874 shares in the last 24 months. This volume of shares sold represents approximately $345.86K in transactions. Related Companies Biomea Fusion Major Shareholders Anebulo Pharmaceuticals Major Shareholders MacroGenics Major Shareholders Cassava Sciences Major Shareholders TScan Therapeutics Major Shareholders Alto Neuroscience Major Shareholders Spero Therapeutics Major Shareholders HilleVax Major Shareholders Connect Biopharma Major Shareholders Skye Bioscience Major Shareholders This page (NASDAQ:TENX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access